ABOUT THE RESEARCHER

OVERVIEW

Lab: Suneet Agarwal Lab

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021 Sep 09; 138(10):898-911. View abstract
  2. Telomerase RNA recruits RNA polymerase II to target gene promoters to enhance myelopoiesis. Proc Natl Acad Sci U S A. 2021 Aug 10; 118(32). View abstract
  3. Hepatic vascular remodelling in a patient with dyskeratosis congenita. Histopathology. 2021 Jul 30. View abstract
  4. Mitochondrial function in development and disease. Dis Model Mech. 2021 Jun 01; 14(6). View abstract
  5. Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 2020 12 24; 136(26):3070-3081. View abstract
  6. Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. J Pediatr. 2021 03; 230:55-61.e4. View abstract
  7. Telomerase RNA processing: Implications for human health and disease. Stem Cells. 2020 Sep 01. View abstract
  8. Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome. Blood. 2020 Aug 17. View abstract
  9. Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival. ERJ Open Res. 2020 Apr; 6(2). View abstract
  10. Impaired reproductive function and fertility preservation in a woman with a dyskeratosis congenita. J Assist Reprod Genet. 2020 May; 37(5):1221-1225. View abstract
  11. Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. Cell Stem Cell. 2020 06 04; 26(6):896-909.e8. View abstract
  12. Understanding the evolving phenotype of vascular complications in telomere biology disorders. Angiogenesis. 2019 02; 22(1):95-102. View abstract
  13. Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita. Hematol Oncol Clin North Am. 2018 Aug; 32(4):669-685. View abstract
  14. Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPR-Cas9 genome editing. Nat Biomed Eng. 2017 11; 1(11):878-888. View abstract
  15. Exudative Vitreoretinopathy in Dyskeratosis Congenita. Ophthalmology. 2017 08; 124(8):1246. View abstract
  16. Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Sci Transl Med. 2017 02 08; 9(376). View abstract
  17. Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. Eur Respir J. 2017 01; 49(1). View abstract
  18. Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies. Ophthalmic Genet. 2017 Jan-Feb; 38(1):51-60. View abstract
  19. Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. PLoS One. 2016; 11(9):e0162409. View abstract
  20. A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. Blood. 2016 10 20; 128(16):2089-2092. View abstract
  21. Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease. J Clin Invest. 2016 09 01; 126(9):3377-82. View abstract
  22. Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component. Nat Genet. 2015 Dec; 47(12):1482-8. View abstract
  23. Simultaneous sequencing of oxidized methylcytosines produced by TET/JBP dioxygenases in Coprinopsis cinerea. Proc Natl Acad Sci U S A. 2014 Dec 02; 111(48):E5149-58. View abstract
  24. Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia. Blood. 2014 Jul 17; 124(3):437-40. View abstract
  25. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells. 2013 Jul; 31(7):1287-97. View abstract
  26. A young adult with aplastic anemia and gray hair. Clin Chem. 2013 Jan; 59(1):47-50. View abstract
  27. The GLIB technique for genome-wide mapping of 5-hydroxymethylcytosine. Nat Protoc. 2012 Oct; 7(10):1909-17. View abstract
  28. CTC1 Mutations in a patient with dyskeratosis congenita. Pediatr Blood Cancer. 2012 Aug; 59(2):311-4. View abstract
  29. Telomere dynamics in dyskeratosis congenita: the long and the short of iPS. Cell Res. 2011 Aug; 21(8):1157-60. View abstract
  30. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011 May 19; 473(7347):394-7. View abstract
  31. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011 Mar 03; 471(7336):63-7. View abstract
  32. Cellular therapy for fanconi anemia: the past, present, and future. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S109-14. View abstract
  33. Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol. 2011 Jun; 127(6):1400-7.e4. View abstract
  34. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010 Dec 09; 468(7325):839-43. View abstract
  35. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010 Dec; 42(12):1113-7. View abstract
  36. Dynamic instability of genomic methylation patterns in pluripotent stem cells. Epigenetics Chromatin. 2010 Sep 24; 3(1):17. View abstract
  37. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010 Jul 02; 7(1):15-9. View abstract
  38. AID for reprogramming. Cell Res. 2010 Mar; 20(3):253-5. View abstract
  39. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature. 2010 Mar 11; 464(7286):292-6. View abstract
  40. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010 Feb; 54(2):273-8. View abstract
  41. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009 May 15; 324(5929):930-5. View abstract
  42. Generation of induced pluripotent stem cells from human blood. Blood. 2009 May 28; 113(22):5476-9. View abstract
  43. Current prospects for the generation of patient-specific pluripotent cells from adult tissues. Regen Med. 2007 Sep; 2(5):743-52. View abstract
  44. Cardiac troponin increases among runners in the Boston Marathon. Ann Emerg Med. 2007 Feb; 49(2):137-43, 143.e1. View abstract
  45. Deletion of a conserved Il4 silencer impairs T helper type 1-mediated immunity. Nat Immunol. 2004 Dec; 5(12):1251-9. View abstract
  46. TID1, a mammalian homologue of the drosophila tumor suppressor lethal(2) tumorous imaginal discs, regulates activation-induced cell death in Th2 cells. Oncogene. 2003 Jul 24; 22(30):4636-41. View abstract
  47. A 3' enhancer in the IL-4 gene regulates cytokine production by Th2 cells and mast cells. Immunity. 2002 Jul; 17(1):41-50. View abstract
  48. Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene. Immunity. 2002 May; 16(5):649-60. View abstract
  49. Cell-type-restricted binding of the transcription factor NFAT to a distal IL-4 enhancer in vivo. Immunity. 2000 Jun; 12(6):643-52. View abstract
  50. Chromatin-based regulatory mechanisms governing cytokine gene transcription. J Allergy Clin Immunol. 1999 Jun; 103(6):990-9. View abstract
  51. Regulation of cytokine gene expression during T cell differentiation. 1999. View abstract
  52. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity. 1998 Dec; 9(6):765-75. View abstract
  53. Long-range transcriptional regulation of cytokine gene expression. Curr Opin Immunol. 1998 Jun; 10(3):345-52. View abstract
  54. Genetic-based strategies for control of HIV-1: Tat and Rev as targets. . Drug News and Perspectives. 1996; 9(4):220-227. View abstract